loading page

Effects of statins and exercise on postprandial lipoproteins in metabolic syndrome vs metabolically healthy individuals
  • +3
  • Laura Alvarez-Jimenez,
  • Ricardo Mora-Rodríguez
Laura Alvarez-Jimenez
Univ Castilla La Mancha

Corresponding Author:[email protected]

Author Profile
Univ Castilla La Mancha
Author Profile
Univ Castilla La Mancha
Author Profile
Univ Castilla La Mancha
Author Profile
Univ Castilla La Mancha
Author Profile
Ricardo Mora-Rodríguez
Univ Castilla La Mancha
Author Profile


Aims: To determine if the combination of exercise and statin could normalize postprandial triglyceridemia (PPTG) in hypercholesteraemic individuals. Mehods: Eight hypercholesteraemic (blood cholesterol 182±38 mg·dL-1; LDL-c 102±32 mg·dL-1) overweight (BMI 30±4 kg·m-2) individuals with metabolic syndrome (i.e., Met Synd) were compared to a group of eight metabolically healthy controls (i.e., MetH, blood cholesterol 149±23 mg·dL-1; LDL-c 77±23 mg·dL-1, and BMI 23±2 kg·m-2). Each group underwent two PPTG tests, either 14-h after a bout of intense exercise (EXER) or without previous exercise (REST). Additionally, Met Synd individuals were tested 96 h after withdrawal of their habitual statin medication (PLAC trials) to study medication effects. Results: A bout of exercise before the test meal did not reduce PPTG in Met Synd (P=0.347), but reduced PPTG by 46% in MetH (224±142 to 413±267 mg·dL-1·for 5 h iAUC; P=0.02). In both trials (i.e., REST and EXER) statin withdrawal in Met Synd greatly increased PPTG (average 65%; P<0.01), mean LDL-c (average 25%; P<0.01), total cholesterol (average 16%; P<0.01) and Apo B48 (24%; P<0.01), without interference from exercise. However, Apo B100 was not affected by statin withdrawal. Conclusions: Hypercholesteraemic Met Synd individuals (compared to metabolically healthy controls) are resistant to the effects of exercise on reducing PPTG. However, chronic statin medication blunts the elevations in TG after a fat meal (i.e., iAUC of PPTG) reducing their cardiovascular risk associated to their atherogenic dyslipidemia. Statin decreases PPTG by reducing the secretion or accelerating the catabolism of intestinal Apo B48.
17 Apr 2020Submitted to British Journal of Clinical Pharmacology
20 Apr 2020Submission Checks Completed
20 Apr 2020Assigned to Editor
23 Apr 2020Reviewer(s) Assigned
15 May 2020Review(s) Completed, Editorial Evaluation Pending
21 May 2020Editorial Decision: Revise Major
28 May 20201st Revision Received
01 Jun 2020Submission Checks Completed
01 Jun 2020Assigned to Editor
01 Jun 2020Review(s) Completed, Editorial Evaluation Pending
04 Jun 2020Editorial Decision: Revise Minor
05 Jun 20202nd Revision Received
08 Jun 2020Submission Checks Completed
08 Jun 2020Assigned to Editor
08 Jun 2020Review(s) Completed, Editorial Evaluation Pending
16 Jun 2020Editorial Decision: Accept